RVMD: revmed.com Price/Earnings to Growth Multiple
Global political tensions are hindering the international exchange of biodata and the conduct of tests. Meanwhile, Revolution Medicines (RVMD) effectively distributes drug synthesis across various contract centers, minimizing dependence on partners. The PEG investment attractiveness indicator demonstrates management's success in raising capital and developing therapies, where the value 0.00 represents the current figure for this metric.
Metric breakdowns and analytics for Revolution Medicines, Inc. (RVMD)
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
Debt to Capital Revolution Medicines|RVMD - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Revolution Medicines, Inc.|RVMD - Company Aggregate Debts|Debts to Book Value Revolution Medicines, Inc.|RVMD - Company Long-Term Liabilities|Company Short-Term Debt Revolution Medicines|Immediate Liquidity revmed.com
- company profitability and valuation multiples indicators:
RVMD - Company Net Income|Expected Profit Revolution Medicines|RVMD - Price to Earnings Ratio|Forward P/E Multiple Revolution Medicines, Inc.|RVMD - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Revolution Medicines Corp|RVMD - Operating profit EBITDA|Net earnings per share for the last four quarters Revolution Medicines|RVMD - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months revmed.com|RVMD - Earnings per share growth in current year|Projected earnings per share growth rate for next year Revolution Medicines
- total revenue and sales volume data:
General company analysis:RVMD - Revolution Medicines
The PEG ratio compares the current P/E multiple with the rate of earnings expansion, allowing for the determination of an asset's fair value adjusted for growth dynamics. By analyzing the normalized PEG multiple, an investor assesses the extent to which the market capitalization of Revolution Medicines (RVMD) aligns with the commercialization potential of its targeted oncology drugs and its success in blocking specific cancer mutations.
Who Revolution Medicines competes with
Price/Earnings to Growth Multiple BeiGene Ltd ONC|PEG Multiple HALO (halozyme.com)|AAPG - Price/Earnings to Growth Multiple|CGON: Price/Earnings to Growth Multiple|URGN - PEG Multiple|Bicara Bio (BCAX) - Price/Earnings to Growth Ratio|Personalis Corp - Growth-Adjusted Payback Ratio|ERAS (Erasca Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Delcath Systems, Inc. DCTH|Price/Earnings to Growth Multiple YMAB (Y-mAbs Corp)|PEG Multiple Aura Bio (AURA)|PEG Multiple CADL (Candel Therapeutics Inc.)|ARAY - Price/Earnings to Growth Multiple|SLS - Price/Earnings to Growth Ratio|Actuate Therapeutics - Company Value to Earnings Growth Ratio|CTOR: PEG Multiple|TuHURA (HURA) - PEG Multiple|TARA (Protara Therapeutics Inc) - PEG Multiple|FATE: Growth-Adjusted Payback Ratio|PEG Multiple WHWK|TCRX (TScan) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Champions Oncology, Inc. CSBR|XBIT - Price/Earnings to Growth Multiple|CEL-SCI - PEG Multiple|OSTX - PEG Multiple|Radiopharm Theranostics Limited (RADX) - Price/Earnings to Growth Ratio|ARTV - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ANL|Price/Earnings to Growth Ratio VERU|PEG Multiple TPST|XLO: Market Cap to Earnings and Growth Ratio|PEG Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Price to Earnings Adjusted for Growth Rate|Kairos Pharma Ltd - PEG Multiple|Market Cap to Earnings and Growth Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Price/Earnings to Growth Ratio|CRIS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple APLM|Tharimmune (THAR) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ADVB (Advanced Biomed Inc.)|Genprex - Growth-Adjusted P/E Ratio|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Price/Earnings to Growth Multiple|Xenetic Bio - PEG Multiple|SLRX - PEG Multiple|PPBT: PEG Multiple|Growth-Adjusted P/E Ratio AONC|BGNE (BeiGene Ltd) - PEG Multiple|CKPT (Checkpoint Therapeutics, Inc) - Company Value to Earnings Growth Ratio|PEG Multiple ELEV|Price/Earnings to Growth Multiple iCAD Corp ICAD|Price/Earnings to Growth Ratio ikenaoncology.com IKNA|NTBL - Price/Earnings to Growth Multiple|VIRX - Price/Earnings to Growth Ratio|MOR - PEG Multiple|NAYA: PEG Multiple|Ascentage Pharma Group (AAPGV) - PEG Multiple
